Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration

Biomaterials

Volumn 33, Issue 3, 2012, Pages 979-988

  Iezzi, Raymond ^a,b   Guru, Bharath R ^c   Glybina, Inna V ^a   Mishra, Manoj K ^c   Kennedy, Alexander ^a   Kannan, Rangaramanujam M ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c Wayne State University   (United States)

Author keywords

Age related macular degenerationRetinitis pigmentosa; Microglia; Neuroinflammation; PAMAM dendrimers; Retinal degeneration

Indexed keywords

MICROGLIA; NEUROINFLAMMATION; PAMAM DENDRIMER; PIGMENTOSA; RETINAL DEGENERATIONS;

ALDEHYDES; CELLS; DENDRIMERS; DRUG DELIVERY; RATS; VISION;

OPHTHALMOLOGY;

DENDRIMER; FLUOCINOLONE ACETONIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CELL COUNT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG STRUCTURE; IN VIVO STUDY; MICROGLIA; NEURITIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; RETINA DEGENERATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DENDRIMERS; ELECTRORETINOGRAPHY; FLUOCINOLONE ACETONIDE; INFLAMMATION; INTRAVITREAL INJECTIONS; NEUROIMMUNOMODULATION; RATS; RETINAL DEGENERATION;

RATTUS;

EID: 81155152766     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.10.010     Document Type: Article

References (52)

1. Rattner A., Nathans J. An evolutionary perspective on the photoreceptor damage response. Am J Ophthalmol 2006, 141(3):558-562.
2. van Soest S., Westerveld A., de Jong P.T., Bleeker-Wagemakers E.M., Bergen A.A. Retinitis pigmentosa: defined from a molecular point of view. Surv Ophthalmol 1999, 43(4):321-334.
3. Rao N.A., Kimoto T., Zamir E., Giri R., Wang R., Ito S., et al. Pathogenic role of retinal microglia in experimental uveoretinitis. Invest Ophthalmol Vis Sci 2003, 44(1):22-31.
4. Gupta N., Brown K.E., Milan A.H. Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Exp Eye Res 2003, 76(4):463-471.
5. Tso M.O., Zhang C., Abler A.S., Chang C.J., Wong F., Chang G.Q., et al. Apoptosis leads to photoreceptor degeneration in inherited retinal dystrophy of RCS rats. Invest Ophthalmol Vis Sci 1994, 35(6):2693-2699.
6. Glybina I.V., Kennedy A., Ashton P., Abrams G.W., Iezzi R. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. Invest Ophthalmol Vis Sci 2010, 51(8):4243-4252.
7. Glybina I.V., Kennedy A., Ashton P., Abrams G.W., Iezzi R. Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide. Invest Ophthalmol Vis Sci 2009, 50(10):4847-4857.
8. Thanos S. Sick photoreceptors attract activated microglia from the ganglion cell layer: a model to study the inflammatory cascades in rats with inherited retinal dystrophy. Brain Res 1992, 588(1):21-28.
9. Zeng H.Y., Zhu X.A., Zhang C., Yang L.P., Wu L.M., Tso M.O. Identification of sequential events and factors associated with microglial activation, migration, and cytotoxicity in retinal degeneration in rd mice. Invest Ophthalmol Vis Sci 2005, 46(8):2992-2999.
10. Choucair N., Laporte V., Levy R., Arnold A.S., Gies J.P., Poindron P., et al. Phagocytic functions of microglial cells in the central nervous system and their importance in two neurodegenerative diseases: multiple sclerosis and Alzheimer's disease. Cent Eur J Biol 2006, 1(4):463-493.
11. Rojo L.E., Fernández J.A., Maccioni A.A., Jimenez J.M., Maccioni R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008, 39(1):1-16.
12. Saadani-Makki F., Kannan S., Lu X., Janisse J., Dawe E., Edwin S., et al. Intrauterine administration of endotoxin leads to motor deficits in a rabbit model: a link between prenatal infection and cerebral palsy. Am J Obstet Gynecol 2008, 199(6):651e1-651e7.
13. Liang F.Q., Aleman T.S., Dejneka N.S., Dudus L., Fisher K.J., Maguire A.M., et al. Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa. Mol Ther 2001, 4(5):461-472.
14. Sieving P.A., Caruso R.C., Tao W., Coleman H.R., Thompson D.J., Fullmer K.R., et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006, 103(10):3896-3901.
15. Wenzel A., Grimm C., Seeliger M.W., Jaissle G., Hafezi F., Kretschmer R., et al. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest Ophthalmol Vis Sci 2001, 42(7):1653-1659.
16. Kompella U.B., Bandi N., Ayalasomayajula S.P. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 2003, 44(3):1192-1201.
17. Dinkel K., MacPherson A., Sapolsky R.M. Novel glucocorticoid effects on acute inflammation in the CNS. J Neurochem 2003, 84(4):705-716.
18. Glezer I., Rivest S. Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist 2004, 10(6):538-552.
19. Behl C., Skutella T., Lezoualc'h F., Post A., Widmann M., Newton C.J., et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997, 51(4):535-541.
20. Dykens J.A., Carroll A.K., Wiley S., Covey D.F., Cai Z.Y., Zhao L., et al. Photoreceptor preservation in the S334ter model of retinitis pigmentosa by a novel estradiol analog. Biochem Pharmacol 2004, 68(10):1971-1984.
21. Dierks D., Lei B., Zhang K., Hainsworth D.P. Electroretinographic effects of an intravitreal injection of triamcinolone in rabbit retina. Arch Ophthalmol 2005, 123(11):1563-1599.
22. Tomalia D.A. In quest of a systematic framework for unifying and defining nanoscience. J Nanopart Res 2009, 11(6):1251-1310.
23. Florence A.T., Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev 2001, 50:s69-s89.
24. Kobayashi H., Brechbiel M.W. Dendrimer-based MRI macromolecular contrast agents: characteristics and applications. Mol Imaging 2003, 2(1):1-10.
25. Lee C.C., MacKay J.A., Frechet J.M., Szoka F.C. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23(12):1517-1526.
26. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6(9):688-701.
27. Hayder M., Poupot M., Baron M., Nigon D., Turrin C.O., Caminade A.M., et al. A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. Sci Transl Med 2011, 3(81). 81ra35.
28. Menjoge A.R., Kannan R.M., Tomalia D.A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 2010, 15(5-6):171-185.
29. Sarin H., Kanevsky A.S., Wu H., Brimacombe K.R., Fung S.H., Sousa A.A., et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med 2008, 6:80. PMC2639552.
30. Duncan R., Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005, 57(15):2215-2237.
31. Sadekar S., Ray A., Janat-Amsbury M., Peterson C.M., Ghandehari H. Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice. Biomacromolecules 2011, 12(1):88-96.
32. Kojima C., Turkbey B., Ogawa M., Bernardo M., Regino C.A., Bryant L.H., et al. Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics. Nanomedicine 2011, 10.1016/j.nano.2011.03.007.
33. 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res 2004, 21(3):476-483.
34. Vandamme T., Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005, 102(1):23-38.
35. Velazquez A., Carnahan M.A., Kristinsson J., Stinnett S., Grinstaff M.W., Kim T. New dendritic adhesives for sutureless ophthalmic surgical procedures: in vitro studies of corneal laceration repair. Arch Ophthalmol 2004, 122(6):867-870.
36. Grinstaff M.W. Designing hydrogel adhesives for corneal wound repair. Biomaterials 2007, 28(35):5205-5214.
37. Marano R.J., Toth I., Wimmer N., Brankov M., Rakoczy P.E. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Nat Gene Ther 2005, 12(21):1544-1550.
38. Jaffe G.J., Ben-Nun J., Guo H., Dunn J.P., Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000, 107(11):2024-2033.
39. Kimura H., Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica 2001, 215(3):143-155.
40. Herrero-Vanrell R., Refojo M.F. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev 2001, 52(1):5-16.
41. Musch D.C., Martin D.F., Gordon J.F., Davis M.D., Kuppermann B.D. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant: the ganciclovir implant study group. N Engl J Med 1997, 337(2):83-90.
42. Kurz D., Ciulla T.A. Novel approaches for retinal drug delivery. Ophthamol Clin North Am 2000, 15(3):405-410.
43. Bourges J.-L., Gautier S.E., Delie F., Bejjani R.A., Jeanny J.C., Gurny R., et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003, 44(8):3562-3569.
44. Dai H., Navath R.S., Balakrishnan B., Guru B.R., Mishra M.K., Romero R., et al. Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers upon subarachnoid administration. Nanomedicine (Lond) 2010, 5(9):1317-1329.
45. Kannan RM, Kannan S, Romero R, Navath RS, Dai H, Kurtoglu YE, et al. Dendrimer-based nanodevices for therapeutic and imaging applications. US patent (#12/797,657) and international PCT (PCT/US10/38068), filed June (2010).
46. Kannan RM, Iezzi R, Kannan S, Guru BR. Dendrimer-containing particles for sustained release of compounds. US provisional patent filed 10/5/07 (Application #60/997987; Regular patents filed in US (#12/681,516), Canada (#2,701,291), European Union (#08835693.6), Japan (#2010-528216) and India (1247/ELNP/2010) (Apr. 2010).
47. Navath R.S., Menjoge A.R., Wang B., Romero R., Kannan S., Kannan R.M. Amino acid-functionalized dendrimers with heterobifunctional chemoselective peripheral groups for drug delivery applications. Biomacromolecules 2010, 11(6):1544-1563.
48. Navath R.S., Kurtoglu Y.E., Wang B., Kannan S., Romero R., Kannan R.M. Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels. Bioconjug Chem 2008, 19(12):2446-2455.
49. Khandare J., Kolhe P., Pillai O., Kannan S., Lieh-Lai M., Kannan R.M. Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates. Bioconjug Chem 2005, 16(2):330-337.
50. Perumal O., Khandare J., Kolhe P., Kannan S., Lieh-Lai M., Kannan R.M. Effects of branching architecture and linker on the activity of hyperbranched polymer-drug conjugates. Bioconjug Chem 2009, 20(5):842-846.
51. Mishra M.K., Kotta K., Hali M., Wykes S., Gerard H.C., Hudson A.P., et al. PAMAM dendrimer-azithromycin conjugate nanodevices for the treatment of Chlamydia trachomatis infections. Nanomedicine 2011, 10.1016/j.nano.2011.04.008.
52. Kannan S., Saadani-Makki F., Balakrishnan B., Dai H., Chakraborty P.K., Janisse J., et al. Decreased cortical serotonin in neonatal rabbits exposed to endotoxin in utero. J Cereb Blood Flow Metab 2011, 31(2):738-749.